Navigation Links
CenterWatch to Introduce Key Findings from Surveys on Physician Referrals to Clinical Trials and Clinical Trial Volunteer Experiences at DIA Meeting
Date:6/18/2009

CenterWatch will present never-before released results from two annual surveys at the upcoming DIA Meeting in San Diego, Calif.

Boston, Mass. (PRWEB) June 18, 2009 -- CenterWatch, a global source for clinical trials information, will present never-before released results from two annual surveys aimed at better understanding physician referrals to clinical trials and study volunteer experiences at DIA's 45th Annual Meeting, June 22-24, 2009, in San Diego, Calif.

CenterWatch's Director of Market Research, Mary Jo Lamberti, Ph.D., will present analysis of 250 physician responses worldwide focusing on factors surrounding physicians' comfort level with referring patients into trials. Her findings will include concerns about trial location, accessibility of a trial for a patient, and general knowledge about a patient's particular disease.

From the volunteer viewpoint, Paul Dewberry, Senior Research Analyst at CenterWatch, will discuss patient experiences in trials across all disease states and will disclose new data on trial participation compensation for study volunteers, which was not previously captured on prior years' surveys. Responses were gathered from approximately 670 volunteers who participated in phase I-IIIb studies, the largest response since the benchmark survey was first released in 2004.

"This year we received more volunteer responses than any other. Additionally, the responses to open-ended questions were superior in quality," Lamberti said. "Patients were more willing to give detailed information which has resulted in much better data and subsequent analysis."

For more information on this presentation and other CenterWatch speaking engagements, visit http://www.centerwatch.com/about-centerwatch/events/index.htm.

About Mary Jo Lamberti, Ph.D.
Mary Jo Lamberti, Ph.D. is the editor of the CenterWatch sourcebook, State of the Clinical Trials Industry and has extensive experience conducting research and evaluation in both academia and in the clinical trials industry. She is a frequent speaker at industry conferences and has published articles in several trade magazines. Dr. Lamberti holds a B.A. from Wellesley College and a Ph.D. from Boston University.

About CenterWatch
Founded in 1994, CenterWatch is a trusted source and global destination for clinical trials information for both professionals and patients. We provide proprietary data and information about clinical trials through a variety of newsletters, books, databases, and information services used by pharmaceutical and biotechnology companies, CROs, SMOs, and investigative sites involved in the management and conduct of clinical trials. CenterWatch was also the first Internet site to publish detailed information about active clinical trials that could be accessed by patients and their advocates. Today, we have one of the largest databases of clinical trials actively seeking patients on the Internet.

###

Read the full story at http://www.prweb.com/releases/2009/06/prweb2541524.htm.


'/>"/>
Source: PRWeb
Copyright©2009 Vocus, Inc.
All rights reserved

Related medicine news :

1. Jobson Medical Information LLC Acquires CenterWatch and New England IRB From Thomson Healthcare
2. HealthFrontier Introduces New Innovation in Web-Based Remote Health Monitoring Technology
3. Texas Institute for Surgery at Presbyterian Hospital of Dallas Introduces the First Wireless OR in DFW
4. Noteworthy Medical Systems Introduces NetPay(TM)
5. Language Technologies Introduces ReadSmart Edition Apps(TM) for the iPhone(TM) and iPod(R) Touch; Unique Apps Improve Ergonomics of Reading while Retaining Look and Design of Print Books
6. CEP America Introduces ER Forum Blog
7. High Activity, Plant Based Diamine Oxidase Enzyme Introduced by Bio-Research Products
8. Autism Family Foundation Introduces The Robert J. Keegan Family Center for Autism
9. Clinical Innovations Introduces New Circumcision Device
10. TOPAZ Technologies Introduces Biosafety Software Solution
11. BellaDerm(TM), a Unique Human Skin Tissue Implant for Facial and Body Contouring, is Introduced by MTF
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/28/2017)... ... March 28, 2017 , ... Revolution for Truth has ... to protect parental rights and civil liberties, and to restore transparency within government ... demonstration coincides with a press conference taking place Friday morning calling on President ...
(Date:3/28/2017)... ... March 28, 2017 , ... Medforce Technologies, Inc., ... to announce it has joined the National Association for Home Care and Hospice ... ill, disabled, and dying Americans of all ages and the caregiver who provide ...
(Date:3/28/2017)... ... March 28, 2017 , ... Z-Medica, LLC, a leading developer ... Center (UPMC) will acquire QuikClot® Bleeding Control Kits® (BCK) to equip up to ... with efforts by the American College of Surgeons, U.S. Department of Defense, Department ...
(Date:3/28/2017)... Switzerland (PRWEB) , ... March 28, 2017 , ... ... for laboratory instruments are critical to ensuring high-quality results and maintaining GMP and ... Qualification of Laboratory Instruments in accordance with GMP requirements " these requirements are ...
(Date:3/28/2017)... San Francisco, CA (PRWEB) , ... March 28, 2017 , ... ... million people suffering from acne, access to quality care can be limited while the ... skincare company that offers customized prescription acne care for every customer online, today released ...
Breaking Medicine News(10 mins):
(Date:3/27/2017)... The National University of Singapore (NUS) ... company, signed a Memorandum of Understanding (MOU) recently ... the region. Under this MOU, ... Technology (BIGHEART) at NUS and Holmusk will establish ... healthcare IT and medical device development. These include ...
(Date:3/27/2017)... 27, 2017  ImMAGE Biotherapeutics (OTCMKTS: IMMG), an early-stage ... early toxicology and efficacy studies. The company is harnessing ... specific protein, MAGE A, in an effort to find ... After 4 weeks of treatment in transgenic ... little toxicity in a full toxicology report of various ...
(Date:3/27/2017)... , March 27, 2017  Sanderling Ventures, portfolio ... Ethicon, a division of Johnson & Johnson. Torax manufactures ... the treatment of gastro-esophageal reflux disease (GERD). The ... (MSA) technology and the procedure is currently available ... Torax Medical was founded by Sanderling Ventures, ...
Breaking Medicine Technology: